Non-Nuclear WldS Determines Its Neuroprotective Efficacy for Axons and Synapses In Vivo

Bogdan Beirowski, Elisabetta Babetto, Jon Gilley, Francesca Mazzola, Laura Conforti, Lucie Janeckova, Giulio Magni, Richard R. Ribchester, Michael P. Coleman

Research output: Contribution to journalArticlepeer-review


Axon degeneration contributes widely to neurodegenerative disease but its regulation is poorly understood. The Wallerian degeneration slow (Wld(S)) protein protects axons dose-dependently in many circumstances but is paradoxically abundant in nuclei. To test the hypothesis that Wld(S) acts within nuclei in vivo, we redistributed it from nucleus to cytoplasm in transgenic mice. Surprisingly, instead of weakening the phenotype as expected, extranuclear Wld(S) significantly enhanced structural and functional preservation of transected distal axons and their synapses. In contrast to native Wld(S) mutants, distal axon stumps remained continuous and ultrastructurally intact up to 7 weeks after injury and motor nerve terminals were robustly preserved even in older mice, remaining functional for 6d. Moreover, we detect extranuclear Wld(S) for the first time in vivo, and higher axoplasmic levels in transgenic mice with Wld(S) redistribution. Cytoplasmic Wld(S) fractionated predominantly with mitochondria and microsomes. We conclude that Wld(S) can act in one or more nonnuclear compartments to protect axons and synapses, and that molecular changes can enhance its therapeutic potential.
Original languageEnglish
Pages (from-to)653-668
Number of pages16
JournalThe Journal of Neuroscience
Issue number3
Publication statusPublished - Jan 2009


  • axon degeneration
  • Wallerian degeneration
  • neurodegeneration
  • low Wallerian degeneration gene
  • neuroprotection
  • neuromuscular junction


Dive into the research topics of 'Non-Nuclear Wld<sup>S</sup> Determines Its Neuroprotective Efficacy for Axons and Synapses <em>In Vivo</em>'. Together they form a unique fingerprint.

Cite this